Rajesh Devraj

Rajesh (Raj) Devraj is a venture partner and focuses on creating and building the next generation of groundbreaking biotech companies.

Most recently, Raj co-founded Disarm Therapeutics with Atlas and served as its chief scientific officer of Disarm Therapeutics, which was acquired by Eli Lilly for up to $1.36 billion including $135 million upfront. Before Disarm, he served as chief scientific officer of Atlas-founded Padlock Therapeutics until its acquisition by BMS for up to $600 million. Previously, Raj served in senior executive roles at Euclises & Deciphera Pharmaceuticals and at Jubilant Life Sciences. Prior to that, Raj spent 14 years in positions of increasing responsibility with Pfizer Global R&D and the legacy Pharmacia and Searle companies. Raj has also served on the boards of directors for several biotech companies.

Over a 25-year career in large pharma and biotech, Raj has led discovery, early clinical development and strategic planning teams that have advanced multiple candidates into clinical trials for refractory cancers, autoimmune diseases, IPF, diabetic nephropathy, COPD, and pain. Raj received his BS in pharmacy from University of Mumbai, and PhD in medicinal chemistry from Duquesne University.

Outside of work, Raj enjoys spending time with his family, is a huge fan of tennis and cricket, is an avid tennis player and wine collector.